Transfusion-related Cost Offsets and Time Burden in Patients with Myelofibrosis on Momelotinib Vs. Danazol from MOMENTUM.
FUTURE ONCOLOGY（2024）
关键词
ACVR1,anemia,cost,danazol,JAK inhibitor,momelotinib,myelofibrosis,time burden,transfusion
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要